Breaking News Instant updates and real-time market news.

LOXO

Loxo Oncology

$166.25

27.3 (19.65%)

, BPMC

Blueprint Medicines

$81.00

-5.12 (-5.95%)

14:44
05/17/18
05/17
14:44
05/17/18
14:44

Loxo Oncology price target raised to $182 from $152 at JMP Securities

JMP Securities analyst Konstantinos Aprilakis raised his price target on Loxo Oncology (LOXO) shares to $182 from $152 after the release of ASCO abstracts featuring "impressive data" for LOXO-292 in patients with RET-fusion cancers. The overall response rate in 46 evaluable patients across all RET alterations and tumor types was 52%, noted Aprilakis, who points out that Blueprint Medicines (BPMC) presented data from the Phase I ARROW trial of BLU-667 in 53 patients with RET-altered solid tumors at the AACR annual meeting in April and the ORR it reported across all patients was 45%. The analyst keeps an Outperform rating on Loxo shares.

LOXO

Loxo Oncology

$166.25

27.3 (19.65%)

BPMC

Blueprint Medicines

$81.00

-5.12 (-5.95%)

  • 01

    Jun

LOXO Loxo Oncology
$166.25

27.3 (19.65%)

04/16/18
04/16/18
UPGRADE
Target $170

Overweight
Loxo Oncology upgraded to Overweight after competitor data at Morgan Stanley
As previously reported, Morgan Stanley analyst Matthew Harrison upgraded Loxo Oncology (LOXO) to Overweight from Equal Weight after competitor Blueprint Medicines (BPMC) provided initial data at the AACR meeting on its RET inhibitor BLU-667 that he believes was at the lower-end of Loxo investors' expectations from a competition standpoint. He now believes Loxo has an opportunity to demonstrate differentiation on both efficacy and safety for LOXO-292 versus BLU-667 when updated data are presented at the ASCO meeting in June. Harrison, who sees the most opportunity for LOXO-292 being a better adverse effect profile, raised his price target on Loxo shares to $170 from $130.
04/16/18
STFL
04/16/18
NO CHANGE
STFL
Buy
Blueprint data leaves 'door wide open' for Loxo's LOXO-292, says Stifel
Stifel analyst Stephen Willey noted that Blueprint Medicines (BPMC) reported data from the dose-escalation portion of its Phase 1 trial of BLU-667 at this weekend's AACR meeting. He believes BLU-667 looks like "a sufficiently viable asset for RET-altered tumors," but he also thinks the data has left the competitive window "wide-open" for Loxo Oncology (LOXO) ahead of preliminary LOXO-292 data expected at the ASCO meeting in June. Loxo's data now potentially could shift sentiment on what consensus has been presuming to be a $1B+ opportunity equally-shared between the two companies, Willey tells investors. He maintains a Buy rating on Loxo shares.
05/09/18
JMPS
05/09/18
NO CHANGE
Target $152
JMPS
Outperform
Loxo Oncology price target increased to $152 from $95 at JMP Securities
JMP Securities analyst Konstantinos Aprilakis raised his price target on Loxo Oncology to $152 from $95 following an update to his financial model after the company's Q1 earnings report, which he said highlighted its pipeline progress. He maintains an Outperform rating on Loxo shares.
05/17/18
STFL
05/17/18
NO CHANGE
Target $190
STFL
Buy
Loxo Oncology price target raised to $190 after ASCO abstracts at Stifel
Stifel analyst Stephen Willey said he believes the preliminary efficacy data on Loxo Oncology's (LOXO) LOXO-292 that was reported in abstracts released last night in anticipation of the ASCO meeting should further distance the candidate from other competitive RET inhibitors. The overall response rate, or ORR, of 52% reported for the 46 evaluable patients harboring RET-altered tumors tops the 46% ORR previously-reported for competitor Blueprint Medicines' (BPMC) BLU-667 at AACR, noted Willey. The analyst, who also thinks the disclosure of this data increases visibility for potential strategic buyers who have historically shown a "willingness to pay top-dollar for long-duration targeted oncology agents," increased his price target on Loxo to $190 from $145 and keeps a Buy rating on the shares.
BPMC Blueprint Medicines
$81.00

-5.12 (-5.95%)

04/16/18
JMPS
04/16/18
NO CHANGE
Target $109
JMPS
Outperform
Blueprint price target raised to $109 after BLU-667 data at JMP Securities
JMP Securities analyst Konstantinos Aprilakis raised his price target on Blueprint Medicines to $109 from $97 after the company presented data from the Phase I ARROW trial of BLU-667 in patients with solid tumors driven by alterations in RET at the American Association for Cancer Research annual meeting. Among all 53 enrolled patients, an "impressive" 41 patients remained on BLU-667 as of the data cutoff date, Aprilakis noted. He reiterates an Outperform rating on Blueprint shares.

TODAY'S FREE FLY STORIES

AZO

AutoZone

$732.74

-14.79 (-1.98%)

, AAP

Advance Auto Parts

$167.64

4.25 (2.60%)

08:54
09/19/18
09/19
08:54
09/19/18
08:54
Recommendations
AutoZone, Advance Auto Parts, O'Reilly Automotive analyst commentary  »

AutoZone price target…

AZO

AutoZone

$732.74

-14.79 (-1.98%)

AAP

Advance Auto Parts

$167.64

4.25 (2.60%)

ORLY

O'Reilly Automotive

$340.65

3.98 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TLRY

Tilray

$154.99

34.79 (28.94%)

08:53
09/19/18
09/19
08:53
09/19/18
08:53
Hot Stocks
Citron says still short Tilray, recent rally 'beyond comprehension' »

Short-seller Citron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROW

T. Rowe Price

$109.29

0.3 (0.28%)

08:53
09/19/18
09/19
08:53
09/19/18
08:53
Conference/Events
T. Rowe Price management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

08:53
09/19/18
09/19
08:53
09/19/18
08:53
Conference/Events
Roth Capital to hold a conference »

4th Annual Datacenter…

08:50
09/19/18
09/19
08:50
09/19/18
08:50
Conference/Events
Canaccord to hold a conference »

Artificial Intelligence…

08:50
09/19/18
09/19
08:50
09/19/18
08:50
General news
U.S. Q2 current account deficit narrowed to -$101.5 B »

U.S. Q2 current account…

08:50
09/19/18
09/19
08:50
09/19/18
08:50
General news
Treasury Action: yields drifted below highs »

Treasury Action: yields…

HEAR

Turtle Beach

$17.75

-1.55 (-8.03%)

08:49
09/19/18
09/19
08:49
09/19/18
08:49
Recommendations
Turtle Beach analyst commentary  »

Turtle Beach 45% pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEA

Lear

$154.96

-2.2 (-1.40%)

08:47
09/19/18
09/19
08:47
09/19/18
08:47
Recommendations
Lear analyst commentary  »

Lear price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TNDM

TNDM

08:47
09/19/18
09/19
08:47
09/19/18
08:47
Conference/Events
Tandem Diabetes management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 27

    Nov

GWPH

GW Pharmaceuticals

$149.14

8.165 (5.79%)

08:47
09/19/18
09/19
08:47
09/19/18
08:47
Recommendations
GW Pharmaceuticals analyst commentary  »

Launch of GW…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

TFX

Teleflex

$269.03

1.81 (0.68%)

08:46
09/19/18
09/19
08:46
09/19/18
08:46
Conference/Events
Teleflex management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 09

    Oct

NVS

Novartis

$85.03

-0.1 (-0.12%)

08:46
09/19/18
09/19
08:46
09/19/18
08:46
Conference/Events
Novartis has a conference call hosted by JPMorgan »

JPMorgan Analyst Vosser …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

SPWH

Sportsman's Warehouse

$6.15

-0.02 (-0.32%)

08:45
09/19/18
09/19
08:45
09/19/18
08:45
Conference/Events
Sportsman's Warehouse management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

08:45
09/19/18
09/19
08:45
09/19/18
08:45
General news
U.S. housing starts rose 9.2% to 1.282 M in August »

U.S. housing starts rose…

SSC

Seven Stars Cloud Group

$4.38

-0.3 (-6.41%)

, CBL

CBL & Associates

$4.34

0.005 (0.12%)

08:45
09/19/18
09/19
08:45
09/19/18
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

SSC

Seven Stars Cloud Group

$4.38

-0.3 (-6.41%)

CBL

CBL & Associates

$4.34

0.005 (0.12%)

MELI

MercadoLibre

$315.06

-7.02 (-2.18%)

SQQQ

ProShares UltraPro Short QQQ

$11.80

-0.3 (-2.48%)

GERN

Geron

$5.48

0.05 (0.92%)

KEY

KeyCorp

$19.74

-0.11 (-0.55%)

CGC

Canopy Growth

$51.77

3.25 (6.70%)

SGYP

Synergy Pharmaceuticals

$1.69

0.005 (0.30%)

SDS

UltraShort S&P500 ProShares

$33.45

-0.41 (-1.21%)

AMJ

American Medical Laboratories Inc

$27.87

0.04 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 01

    Oct

  • 13

    Oct

  • 18

    Oct

  • 30

    Oct

  • 30

    Oct

08:45
09/19/18
09/19
08:45
09/19/18
08:45
General news
FX Action: The dollar »

FX Action: The dollar was…

08:45
09/19/18
09/19
08:45
09/19/18
08:45
General news
U.S. Q2 current account deficit narrowed to -$101.5 B »

U.S. Q2 current account…

ATHN

Athenahealth

$135.25

-8.005 (-5.59%)

08:43
09/19/18
09/19
08:43
09/19/18
08:43
Recommendations
Athenahealth analyst commentary  »

Leerink sees risk of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEIC

SEI Investments

$62.66

0.26 (0.42%)

08:42
09/19/18
09/19
08:42
09/19/18
08:42
Conference/Events
SEI Investments management to meet with Oppeheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

08:40
09/19/18
09/19
08:40
09/19/18
08:40
Conference/Events
The Atlanta Society of Finance & Investment Professionals to hold a meeting »

The Atlanta Society of…

OCFC

OceanFirst Financial

$28.39

-0.16 (-0.56%)

, SBBX

SB One Bancorp

$26.10

-0.5 (-1.88%)

08:39
09/19/18
09/19
08:39
09/19/18
08:39
Conference/Events
DA Davidson to hold a conference »

The Mid-Atlantic…

OCFC

OceanFirst Financial

$28.39

-0.16 (-0.56%)

SBBX

SB One Bancorp

$26.10

-0.5 (-1.88%)

WSFS

WSFS Financial

$47.93

-0.475 (-0.98%)

MBCN

Middlefield Banc

$47.35

-1.15 (-2.37%)

FFDF

FFD Financial

$0.00

(0.00%)

WSBC

WesBanco

$45.70

-0.74 (-1.59%)

EMCF

Emclaire Financial

$37.00

-0.45 (-1.20%)

TSC

TriState Capital

$28.40

-0.25 (-0.87%)

STBA

S&T Bancorp

$45.27

(0.00%)

SMMF

Summit Financial Group

$24.75

0.39 (1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 24

    Sep

  • 23

    Oct

CSII

Cardiovascular Systems

$38.05

0.47 (1.25%)

08:39
09/19/18
09/19
08:39
09/19/18
08:39
Recommendations
Cardiovascular Systems analyst commentary  »

Cardiovascular Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

AMRX

Amneal Pharmaceuticals

$23.46

0.62 (2.71%)

, JAZZ

Jazz Pharmaceuticals

$161.89

0.92 (0.57%)

08:38
09/19/18
09/19
08:38
09/19/18
08:38
Recommendations
Amneal Pharmaceuticals, Jazz Pharmaceuticals, Mylan, Amgen, Teva analyst commentary  »

Leerink…

AMRX

Amneal Pharmaceuticals

$23.46

0.62 (2.71%)

JAZZ

Jazz Pharmaceuticals

$161.89

0.92 (0.57%)

MYL

Mylan

$37.80

0.59 (1.59%)

AMGN

Amgen

$202.32

1.5 (0.75%)

TEVA

Teva

$24.50

1.06 (4.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 01

    Oct

  • 17

    Oct

  • 22

    Oct

  • 27

    Oct

  • 09

    Nov

  • 13

    Nov

  • 27

    Nov

  • 20

    Dec

MGRC

McGrath RentCorp

$52.86

-0.15 (-0.28%)

08:37
09/19/18
09/19
08:37
09/19/18
08:37
Initiation
McGrath RentCorp initiated  »

McGrath RentCorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.